Fenwick represented Royalty Pharma (Nasdaq: PRRX), a buyer of biopharmaceutical royalties and funder of innovation across the biopharmaceutical industry, on IP diligence matters relating to its royalty monetization agreement with BRAIN Biotech AG. BRAIN Biotech is the maker of the investigational compound deucrictibant, which is currently in clinical development for the treatment of hereditary angioedema. This funding will allow BRAIN Biotechnologies to continue its accelerating pace of growth.
Under the terms of the agreement, BRAIN Biotech will receive an upfront payment of €18.4 million ($20 million), with additional potential regulatory milestones of up to €18.4 million ($20 million) and further potential long-term sales related milestones of up to €92 million ($100 million). More information about the transaction is available in the press release.
The Fenwick team included partner Dr. Carl Morales and associate Dr. Stefan Ochiana.